share_log

SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Gene Salkind(53.1%)

SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Gene Salkind(53.1%)

SC 13D/A：超過5%持股股東披露文件(修正)-Gene Salkind(53.1%)
美股SEC公告 ·  08/23 04:05

Moomoo AI 已提取核心訊息

On August 6, 2024, Dr. Gene Salkind, a practicing neurosurgeon and Chairman of the Board of Mobiquity Technologies, Inc., filed an amendment to the Schedule 13D, disclosing a significant ownership stake in the company. The filing, which is an update to a previous Schedule 13D filing, indicates that Dr. Salkind, along with his wife and a family trust, beneficially owns 8,805,239 common shares of Mobiquity Technologies, representing approximately 53.1% of the company's outstanding common shares. This ownership includes convertible notes, options, and warrants for additional shares. The filing also notes that Dr. Salkind has no current plans that would result in any major changes to the company's structure or operations as outlined in the Schedule 13D instructions. The acquisition of shares by Dr. Salkind and his associated parties was funded through personal funds over several years. Notably, the reporting person received 7,675,160 common shares upon the automatic conversion of Series H Preferred Stock after the company's stock traded above $2 per share between July 24, 2024, and August 6, 2024. This conversion also included additional shares for accrued and unpaid dividends.
On August 6, 2024, Dr. Gene Salkind, a practicing neurosurgeon and Chairman of the Board of Mobiquity Technologies, Inc., filed an amendment to the Schedule 13D, disclosing a significant ownership stake in the company. The filing, which is an update to a previous Schedule 13D filing, indicates that Dr. Salkind, along with his wife and a family trust, beneficially owns 8,805,239 common shares of Mobiquity Technologies, representing approximately 53.1% of the company's outstanding common shares. This ownership includes convertible notes, options, and warrants for additional shares. The filing also notes that Dr. Salkind has no current plans that would result in any major changes to the company's structure or operations as outlined in the Schedule 13D instructions. The acquisition of shares by Dr. Salkind and his associated parties was funded through personal funds over several years. Notably, the reporting person received 7,675,160 common shares upon the automatic conversion of Series H Preferred Stock after the company's stock traded above $2 per share between July 24, 2024, and August 6, 2024. This conversion also included additional shares for accrued and unpaid dividends.
2024年8月6日，神經外科醫生、Mobiquity Technologies, Inc.董事會主席Gene Salkind博士提交了一份修訂的13D表，披露了對該公司的重要所有權。這份申報文件是對先前的13D表的更新，表明Salkind博士及其妻子以及家族信託共同持有Mobiquity Technologies 8,805,239股普通股，約佔公司已發行普通股的53.1%。該持股包括可轉換票據、期權和附加股權。申報文件還指出，Salkind博士目前沒有計劃導致公司結構或業務出現任何重大變化，如13D表說明所述。Salkind博士及其相關方通過個人資金多年來資助了所持股權的收購。值得注意的是，報告人在2024年7月24日至8月6日之間，當公司股票交易價格超過每股2美元時，收到了7,675,160股普通股，這是H系列優先股自動轉換後得到的。此次轉換還包括應計未付股息的額外股份。
2024年8月6日，神經外科醫生、Mobiquity Technologies, Inc.董事會主席Gene Salkind博士提交了一份修訂的13D表，披露了對該公司的重要所有權。這份申報文件是對先前的13D表的更新，表明Salkind博士及其妻子以及家族信託共同持有Mobiquity Technologies 8,805,239股普通股，約佔公司已發行普通股的53.1%。該持股包括可轉換票據、期權和附加股權。申報文件還指出，Salkind博士目前沒有計劃導致公司結構或業務出現任何重大變化，如13D表說明所述。Salkind博士及其相關方通過個人資金多年來資助了所持股權的收購。值得注意的是，報告人在2024年7月24日至8月6日之間，當公司股票交易價格超過每股2美元時，收到了7,675,160股普通股，這是H系列優先股自動轉換後得到的。此次轉換還包括應計未付股息的額外股份。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    超微電腦
    SMCI
    -- 42.000
    特斯拉
    TSLA
    -- 357.090
    英偉達
    NVDA
    -- 138.630
    MicroStrategy
    MSTR
    -- 380.300
    英特爾
    INTC
    -- 23.930

    解鎖榜首股票